Shobana Balasingam is the Research Lead for the Human Infection Study Programme at Wellcome and has been leading the programme since 2018 which has funded these studies to be established for a range of diseases such as vivax malaria, shigella and hookworm across Asia, Africa and in Brazil as well as COVID challenge studies in the UK. Shobana has over 20 years of experience with human infection studies primarily with influenza, human rhinovirus (HRV) and respiratory syncytial virus (RSV) gained whilst working at hVIVO Ltd (previously known as Retroscreen Virology Ltd). Before joining Wellcome, Shobana was based in Singapore at the Lee Kong Chian School of Medicine where the focus was to establish an influenza human infection study.